Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.
Nuvaira, a US-based developer of treatments for obstructive lung diseases, closed a $79m series E round on Monday led by venture capital firm US Venture Partners.
The round also featured venture capital firms Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, Advanced Technology Ventures (ATV), Split Rock Partners and Windham Venture Partners as well as philanthropic outfit Richard King Mellon Foundation.
Investment firms Morgenthaler Ventures and company builder Versant Ventures also took part, as did Vertex Venture, the venture…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
